Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
65
Language
English
Published on
04/05/21
You may also be interested by these reports :
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...